We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
FibroBiologics Inc | NASDAQ:FBLG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.14 | -1.14% | 12.18 | 9.03 | 14.70 | 12.88 | 12.0178 | 12.50 | 33,138 | 01:00:00 |
HOUSTON, Feb. 29, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics") a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2023, with the U.S. Securities and Exchange Commission.
The filing can be viewed through a link on FibroBiologics' website at https://ir.fibrobiologics.com/sec-filings/annual-reports. Upon written request, stockholders may receive, free of charge, a paper copy of FibroBiologics' Annual Report on Form 10-K (including complete audited financial statements). Requests should be communicated in writing to FibroBiologics, Attention: Investor Relations, 455 E. Medical Center Blvd, Suite 300, Houston, TX 77598.
About FibroBiologics
Based in Houston, FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson or Harrison Seidner, Ph.D.
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-files-2023-form-10-k-annual-report-302076516.html
SOURCE FibroBiologics
Copyright 2024 PR Newswire
1 Year FibroBiologics Chart |
1 Month FibroBiologics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions